RxDoctor Payments Data

Craig Sweeney, DO

Pain Medicine · Great Falls, MTNPI 1275761348

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Nevro Corp. at 33.4% of the total. Reporting peaked in 2019 at $377 and has fallen 60.4% since, to $149 in 2025.

$1,078in general payments, 2019–2025

Across 24 payments — averaging $44.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$359
  • Boston Scientific$225
  • Pacira Pharmaceuticals Incorporated$209
  • Abbott$155
  • Mindray DS USA, Inc.$31
  • Bioventus LLC$28
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$1,078100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain medicine providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$189,835
Medicare patients
591
Services billed
8,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine53$12,441
Pregabalin495$7,517
Gabapentin345$4,734
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen169$3,846
FingolimodFingolimod Hcl12$3,500
Morphine Sulfate ErMorphine Sulfate27$3,186
Tramadol Hcl336$2,361
Celecoxib136$2,232
Tramadol Hcl ErTramadol Hcl24$1,198
Meloxicam192$947
Tizanidine Hcl113$913
Diclofenac Sodium34$912
Duloxetine Hcl65$830
Lidocaine11$642
Nabumetone34$315

Paid to pharmacies, not to this prescriber.

Other pain medicine in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →